Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2081 - Raltitrexed Versus 5-fluorouracil with Cisplatin And Concurrent Radiotherapy (CCRT)For Locally Advanced Head And Neck Squamous Cell Carcinoma(LA-HNSCC): A Randomized Controlled Multi-centered Trial

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Surgical Oncology;  Radiation Oncology;  Head and Neck Cancers

Presenters

Xia He

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

X. He1, H. Yin2, W. Guo1, X. Sun3, X. Hu2, P. Yan1, F. Li1, S. Huang1, H. Zhou4, F. Zhang5, B. Wang6, X. Bian1, Q. Wei1, J. Wu1, F. Wang1, D. Song1, J. Liu1, B. Zhou3

Author affiliations

  • 1 Department Of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 210009 - Nanjing/CN
  • 2 Department Of Radiotherapy Oncology, Xuzhou Central Hospital, Affiliated to School of Medicine,Southeast University, 221009 - Xuzhou/CN
  • 3 Department Of Radiotherapy, Cancer Center of PLA 81 Hospital, 210002 - Nanjing/CN
  • 4 Department Of Radiotherapy Oncology, Nanjing BenQ Hospital, 210019 - Nanjing/CN
  • 5 Department Of Radiotherapy Oncology, Fourth People's Hospital of Wuxi, 214062 - wuxi/CN
  • 6 Department Of Radiotherapy Oncology, Northern Jiangsu Province People's Hospital, 225001 - Yangzhou/CN
More

Resources

Abstract 2081

Background

CCRT has been considered to be the standard of treatment for LA-HNSCC. However, patients receiving CCRT experience a substantial number of treatment-related adverse events, primarily causing oropharyngeal mucositis(OM) and leading to interruption or discontinuation of treatment. Raltitrexed is a specific thymidylate synthase inhibitor with a convenient administration, acceptable toxicity and radiosensitizing property, as the published phase I/II trials have shown. This study aimed to compare the clinical efficacy and toxicity of cisplatin with raltitrexed (RP) or 5-fluorouracil (FP) for LA-HNSCC.

Methods

Eligible patients with LA-HNSCC were randomly assigned in a 1:1 ratio to receive CCRT with either RP or FP. The RP group consisted of 2.5mg/m2 intravenous raltitrexed on day 1 and 25 mg/m2 intravenous cisplatin on days 1-3. The FP group consisted of continuous intravenous infusions of 600 mg/m2 5-fluorouracil on days 1-5 and 25 mg/m2 intravenous cisplatin on days 1-3. Chemotherapy was administrated concurrently with radiotherapy and was repeated every 3 weeks with completion of at least 2 cycles. Primary endpoint was PFS. Secondary endpoints were complete response rates(CRR), OS and safety.

Results

A total of 108 patients with LA-HNSCC enrolled in this study, with 52 patients assigned to the RP group and 56 patients to the FP group. There was no significant difference in CRR between the two arms (42.9% vs 26.8%, respectively, p = 0.074), with the RP group showing a trend of increased CRR. Data of locoregional control, patterns of failure, and survival required further follow-up. The most frequent acute toxicities were bone marrow suppression, gastrointestinal side effects and OM in both arms. The incidence rate of severe OM was significantly lower (P0.05).

Conclusions

The efficacy of the RP regimen was similar to that of the FP regimen. The RP regimen had a tolerable safety profile, with a lower incidence of severe OM and, consequently, an improved quality of life. In conclusion, RP is an effective, well-tolerated regimen for LA-HNSCC.

Clinical trial identification

NCT02485548 Release date: June 26, 2015

Legal entity responsible for the study

Xia He

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.